Search Results for: Influenza

856 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
DLG2 and GRID1 discs large MAGUK scaffold protein 2 glutamate ionotropic receptor delta type subunit 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
DLG2 and GRIN1 discs large MAGUK scaffold protein 2 glutamate ionotropic receptor NMDA type subunit 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG2 and GRIN2A discs large MAGUK scaffold protein 2 glutamate ionotropic receptor NMDA type subunit 2A
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • MECP2 regulates neuronal receptors and channels
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Glycine
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Felbamate
  • Gabapentin
  • Memantine
  • Halothane
  • Phenobarbital
  • Tenocyclidine
  • Prasterone
  • Milnacipran
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG2 and GRIN2B discs large MAGUK scaffold protein 2 glutamate ionotropic receptor NMDA type subunit 2B
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • MECP2 regulates neuronal receptors and channels
  • Activated NTRK2 signals through FYN
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Haloperidol
  • Acamprosate
  • Felbamate
  • Gabapentin
  • Memantine
  • Phenobarbital
  • Tenocyclidine
  • Prasterone
  • Taurine
  • Milnacipran
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG2 and GRIN2D discs large MAGUK scaffold protein 2 glutamate ionotropic receptor NMDA type subunit 2D
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Orphenadrine
  • Phenobarbital
  • Tenocyclidine
  • Prasterone
  • Milnacipran
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG2 and NOS1 discs large MAGUK scaffold protein 2 nitric oxide synthase 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • ROS and RNS production in phagocytes
  • Nitric oxide stimulates guanylate cyclase
  • Ion homeostasis
  • L-Citrulline
  • L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
  • Formic Acid
  • 3-Bromo-7-Nitroindazole
  • N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine
  • N-(3-(Aminomethyl)Benzyl)Acetamidine
  • L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
  • N-Isopropyl-N'-Hydroxyguanidine
  • N-Omega-Propyl-L-Arginine
  • N-Butyl-N'-Hydroxyguanidine
  • S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
  • N-Omega-Hydroxy-L-Arginine
  • Flavin adenine dinucleotide
  • Riboflavin Monophosphate
  • N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine
  • 2'-Monophosphoadenosine 5'-Diphosphoribose
  • S-Ethyl-N-Phenyl-Isothiourea
  • N5-(1-Imino-3-Butenyl)-L-Ornithine
  • 5-N-Allyl-Arginine
  • Nitroarginine
  • NXN-188
  • N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
  • N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
  • Methylene blue
DLG2 and LIN7A discs large MAGUK scaffold protein 2 lin-7 homolog A, crumbs cell polarity complex component
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Dopamine Neurotransmitter Release Cycle
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
DLG2 and SEMA4C discs large MAGUK scaffold protein 2 semaphorin 4C
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
DMD and CADPS dystrophin calcium dependent secretion activator
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Calcium Citrate
  • Calcium Phosphate
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and SGCZ dystrophin sarcoglycan zeta
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and KRT8 dystrophin keratin 8
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Keratinization
  • Formation of the cornified envelope
  • Tenecteplase
  • Copper
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and DGKZ dystrophin diacylglycerol kinase zeta
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Effects of PIP2 hydrolysis
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and CTNNAL1 dystrophin catenin alpha like 1
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and PGM5 dystrophin phosphoglucomutase 5
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and TRAF3IP1 dystrophin TRAF3 interacting protein 1
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Intraflagellar transport
  • Intraflagellar transport
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and DISC1 dystrophin DISC1 scaffold protein
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and KRT19 dystrophin keratin 19
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Keratinization
  • Formation of the cornified envelope
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and DTNA dystrophin dystrobrevin alpha
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and DTNB dystrophin dystrobrevin beta
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)
DMD and KCNJ12 dystrophin potassium inwardly rectifying channel subfamily J member 12
  • Non-integrin membrane-ECM interactions
  • Striated Muscle Contraction
  • Activation of G protein gated Potassium channels
  • Classical Kir channels
  • Phase 4 - resting membrane potential
  • Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
  • Dofetilide
  • Yohimbine
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)
  • Dilated cardiomyopathy (DCM)

Page 18 out of 43 pages